Payment overview · 2025
General Payments
$362.37
13 reported records · 9 companies
Healthcare provider profile · identity verified
Richard D Smith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MONROE, LA · NPI 1053350009
Verified facts
What the public records show
CMS Open Payments records show Richard D Smith, M.D. received $362.37 in general payments during 2025 across 13 reported records.
Inspire Medical Systems, Inc. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $134.96 | 37.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.99 | 16.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.90 | 12.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.53 | 7.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.23 | 6.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.87 | 6.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.27 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.72 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.90 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $362.37 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $134.96 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $45.52 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 684 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 191 |
| Losartan Potassium | Losartan Potassium | 500 | 151 |
| Pravastatin Sodium | Pravastatin Sodium | 392 | 115 |
| Metformin Hcl | Metformin Hcl | 384 | 110 |
| Furosemide | Furosemide | 338 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 92 |
| Carvedilol | Carvedilol | 310 | 88 |
| Simvastatin | Simvastatin | 303 | 85 |
| Nifedipine Er | Nifedipine | 262 | 82 |
| Omeprazole | Omeprazole | 260 | 70 |
| Potassium Chloride | Potassium Chloride | 243 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 64 |
| Gabapentin | Gabapentin | 203 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 53 |
| Benazepril Hcl | Benazepril Hcl | 186 | 54 |
| Glipizide | Glipizide | 178 | 54 |
| Naproxen | Naproxen | 173 | 46 |
| Eliquis | Apixaban | 168 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 51 |
| Lisinopril | Lisinopril | 158 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 44 |
| Alendronate Sodium | Alendronate Sodium | 145 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 45 |
| Clonidine Hcl | Clonidine Hcl | 126 | 42 |
| Allopurinol | Allopurinol | 117 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 104 | 28 |
| Alprazolam | Alprazolam | 100 | 24 |
| Meloxicam | Meloxicam | 100 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 48 |
| Donepezil Hcl | Donepezil Hcl | 95 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 31 |
| Famotidine | Famotidine | 85 | 24 |
| Memantine Hcl | Memantine Hcl | 82 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 27 |
| Trulicity | Dulaglutide | 81 | 13 |
| Mounjaro | Tirzepatide | 75 | 15 |
| Ramipril | Ramipril | 72 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 25 |
| Atenolol | Atenolol | 67 | 19 |
| Irbesartan | Irbesartan | 67 | 18 |
| Ozempic | Semaglutide | 67 | 13 |
| Montelukast Sodium | Montelukast Sodium | 65 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 19 |
| Linzess | Linaclotide | 63 | 20 |
| Valsartan | Valsartan | 61 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Ibuprofen | Ibuprofen | 59 | 30 |
| Jardiance | Empagliflozin | 58 | 13 |
| Clonazepam | Clonazepam | 56 | 13 |
| Spironolactone | Spironolactone | 54 | 17 |
| Ezetimibe | Ezetimibe | 53 | 16 |
| Finasteride | Finasteride | 50 | 16 |
| Sertraline Hcl | Sertraline Hcl | 50 | 18 |
| Levetiracetam | Levetiracetam | 49 | 14 |
| Chlorthalidone | Chlorthalidone | 46 | 17 |
| Trazodone Hcl | Trazodone Hcl | 46 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 15 |
| Bumetanide | Bumetanide | 41 | 13 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 41 | 21 |
| Lovastatin | Lovastatin | 39 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 37 |
| Lorazepam | Lorazepam | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 11 |
| Prednisone | Prednisone | 35 | 19 |
| Colchicine | Colchicine | 34 | suppressed |
| Clotrimazole | Clotrimazole | 32 | 17 |
| Fluconazole | Fluconazole | 32 | 19 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Clonidine | Clonidine | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Celecoxib | Celecoxib | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $362.37 · 13 records | Inspire Medical Systems, Inc. | CAPLYTA, EPKINLY, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, IMBRUVICA, INSPIRE, JASCAYD, KEVEYIS, Ozempic, Rybelsus, VRAYLAR, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error